Skip to main content

Articles

FDA Approvals
Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable Non–Small Cell Lung Cancer
Read More
Online Only
Oncology, Original Research
The Hidden Inferno: Burn Pit Exposure in the Military and Its Potential Links to Cancer
Claire Szewczyk
Read More
Introduction
Welcome to the 2023 PAYERS’ GUIDE TO FDA UPDATES: Latest Approvals, Upcoming Decisions
Read More
A Payer Perspective
Challenges Facing the US Healthcare System in 2023 and Beyond: A Payer Perspective
Gary M. Owens, MD
Read More
FDA Approvals
IMJUDO (Tremelimumab-actl) in Combination With IMFINZI (Durvalumab) Receives FDA Approval for HCC and NSCLC
Jerm Day-Storms, PhD, MWC
Read More
FDA Approvals
FDA Approval of SYFOVRE (Pegcetacoplan) and IZERVAY (Avacincaptad Pegol) Reshapes Management of GA
Jerm Day-Storms, PhD, MWC
Read More
FDA Approvals
FDA Pipeline, October-December 2023
Read More
FDA Approvals
FDA Approvals of Brand-Name Prescription Drugs, October 4, 2022, Through August 4, 2023
Read More
FDA Approvals
FDA Approved Izervay for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Read More
FDA Approvals, Bispecific Antibodies
FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Read More
Page 8 of 244
Results 71 - 80 of 2434